Cutting edge liver health management program

    Best practices for revitalizing liver

    Practice impact calculator

    Please fill in all fields below:

    Our Healthy Program

    Find out more about the program, its outcomes and the benefits it has provided to patients and physicians.

    Woman playing with an appleWoman playing with an appleWoman playing with an apple

    Check out our recommended articles

    Trending topics on liver health

    Obese man with measuring tape

    Obesity Has Reached Crisis Proportions

    Understanding the Alarming Scale of the Obesity Problem

    Clinician using microscope

    Latest NAFLD Practice guidelines by AGA

    Clinical care Pathway for the risk stratification and management of patients with NAFLD

    FibroScan device

    A Liver Scan on the Drive-Thru Menu?

    Non-invasive liver tests track lifestyle changes for better liver health

    Surfing the NASH Tsunami Podcast

    Expanding Benefits in FibroScan® Use and Integrating Digital Tools

    Navigating the Future of Liver Health: FibroScan®, Data Integration, and Patient Care

    Meet us at these upcoming events

     Emerging Topic Conference: Precision Medicine in MASLD

    Emerging Topic Conference: Precision Medicine in MASLD

    Las Vegas, Nevada

    Learn about AASLD's upcoming Emerging Topic Conference being held at the Four Seasons in Las Vegas, on Precision Medicine in MASLD.

    EASL Congress 2024

    EASL Congress 2024

    Milan, Italy

    Europe's biggest hepatology event, EASL Congress 2024, unites 7,000+ professionals in Milan (and online) for 4 days of learning, networking & research sharing. Join world-class faculty & shape the future of liver disease care!

    Today 25-30% of the general population are estimated to have NAFLD, most being undetected. With the expected rise of NAFLD prevalance by 2030, NASH is projected to DOUBLE. 
    Current clinical guideliness recommend:A NAFLD screening should be part of a routine work-up in high-risk patients! Patients having Type 2 diabetes, obesity, and/or metabolic syndrome.

    Two Companies, One Mission

    Providing a complementary approach to managing and monitoring

    chronic liver deseases, which may lead to improve patient outcomes.


    Innovation dedicated to liver health, offering FibroScan®,

    the leading non-invasive liver testing solution.

    1Asset 10

    The leader in digital therapeutics providing a scalable

    NAFLD clinical service line.